As demonstrated by recent experimental and preclinical studies15, when BRAF inhibitors (BRAF-I), such as Vemurafenib and Dabrafenib, are administered to cancer patients with BRAF mutations, they can induce drug-sensitive cancer cells to secrete resistance factors (e.g., IGF and HGF) into the tumor microenvironment. Here, HGF is linked to neoplasm.